PPCB Propanc Biopharma, Inc.
$2.11▼ -13.17%
Healthcare
Other
Volume 73.7K
Avg Volume (10D) 54.0K
Key Metrics & Fundamentals
Market Cap
$2.18M
P/E Ratio
0.0
Div Yield
0.00%
52W Range
2.09 - 353.75
% vs 50 MA
166.24%
% vs 200 MA
-4.74%
RSI-14
74.9
MACD Histogram
+0.2700
Beta (1Y vs SPY)
-3.23
Free Cash Flow
-$1.60M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$3.68M
COGS
–
Operating Exp
$3.46M
Operating Income
-$3.46M
EBIT
-$3.46M
Pretax Income
-$4.57M
Net Income
-$4.57M
Price & Volume History
Loading chart…
Recent News
Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients
GlobeNewswire · Oct 28, 2026 8:30 AM ET
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
GlobeNewswire · Oct 26, 2026 8:30 AM ET
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
GlobeNewswire · Oct 22, 2026 4:24 PM ET
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
GlobeNewswire · Oct 22, 2026 8:30 AM ET
Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
GlobeNewswire · Oct 16, 2026 8:36 AM ET
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
GlobeNewswire · Oct 14, 2026 8:30 AM ET
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
GlobeNewswire · Oct 7, 2026 8:30 AM ET
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
GlobeNewswire · Sep 29, 2026 8:30 AM ET
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
GlobeNewswire · Sep 22, 2026 8:30 AM ET
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
GlobeNewswire · Sep 16, 2026 8:30 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See PPCB's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.